REGENXBIO

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell REGENXBIO and other ETFs, options, and stocks.

About RGNX

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. 

CEO
Kenneth T. Mills
CEOKenneth T. Mills
Employees
344
Employees344
Headquarters
Rockville, Maryland
HeadquartersRockville, Maryland
Founded
2008
Founded2008
Employees
344
Employees344

RGNX Key Statistics

Market cap
793.19M
Market cap793.19M
Price-Earnings ratio
-2.66
Price-Earnings ratio-2.66
Dividend yield
Dividend yield
Average volume
456.08K
Average volume456.08K
High today
$16.44
High today$16.44
Low today
$15.72
Low today$15.72
Open price
$16.20
Open price$16.20
Volume
305.66K
Volume305.66K
52 Week high
$28.80
52 Week high$28.80
52 Week low
$11.83
52 Week low$11.83

RGNX News

Simply Wall St 1d
REGENXBIO Inc. Not Doing Enough For Some Investors As Its Shares Slump 26% - Simply Wall St

The REGENXBIO Inc. ( ) share price has softened a substantial 26% over the previous 30 days, handing back much of the gains the stock has made lately. Instead o...

REGENXBIO Inc. Not Doing Enough For Some Investors As Its Shares Slump 26% - Simply Wall St

Analyst ratings

92%

of 12 ratings
Buy
91.7%
Hold
8.3%
Sell
0%
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.